touchREVIEWS in Oncology & Haematology – Volume 22, Issue 2 – 2026
Foreword
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue reflects the growing momentum of precision oncology, from liquid biopsy and response-adapted strategies to antibody–drug conjugates (ADCs) and immune-based therapies, alongside the challenges of translating these advances into routine, equitable care. We open with an editorial […]
Editorials
Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential for minimal residual disease (MRD) detection and recurrence monitoring. In metastatic breast cancer (MBC), ctDNA […]
Choosing the appropriate adjuvant therapy in patients with melanoma undergoing neoadjuvant treatment
This article examines current evidence supporting the use of neoadjuvant immunotherapy in patients with resectable macroscopic stage III melanoma and critically discusses the selection of appropriate adjuvant therapy following surgery. It is written in the context of emerging evidence from recent neoadjuvant trials, both in melanoma and across multiple tumor types, suggesting that pathologic response […]
Reviews
Urothelial carcinoma (UC) is the 11th most common cancer in the UK, with approximately 11,000 new bladder cancer diagnoses annually.1 Globally, bladder cancer accounts for approximately 635,000 new diagnoses and 228,000 deaths annually, based on the latest GLOBOCAN estimates for 2024.2 Bladder cancer constitutes the vast majority of urothelial malignancies (90–95%), with upper tract urothelial […]
Metastatic triple-negative breast cancer (mTNBC) is a clinically heterogeneous disease, but compared with other breast cancer subtypes, triple-negative breast cancer (TNBC) is generally associated with a poorer prognosis and has historically had limited therapeutic options.1 The 5-year survival rate remains only 14.9%, and some patients are unable to proceed to second-line or later-line therapies because […]
Gastrointestinal (GI) cancers constitute a major contributor to global cancer incidence and mortality and remain among the leading causes of cancer–related death worldwide despite advances in prevention, screening and supportive care.1,2 Collectively encompassing malignancies of the esophagus, stomach, liver, biliary tract, pancreas and colorectum, these tumors account for a disproportionate share of advanced–stage diagnoses and […]
Esophageal cancer (EC) is a major global health concern, ranking as the 11th most commonly diagnosed cancer and the seventh leading cause of cancer-related deaths worldwide, with an estimated 494,320 new cases and 441,994 deaths in 2024.1 Esophageal squamous cell carcinoma (ESCC) remains the predominant subtype globally (84% of new cases), while esophageal adenocarcinoma (EAC) […]
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in the USA and Western Europe.1,2 DLBCL is treated with curative intent given the aggressive nature of the disease. Rituximab (R), cyclophosphamide (C), doxorubicin (H), vincristine (O) and prednisone (P) (R-CHOP) has been the bedrock of therapy for patients with DLBCL since the pivotal study […]
Trending Topic
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue reflects the growing momentum of precision oncology, from liquid biopsy and response-adapted strategies to antibody–drug conjugates (ADCs) and immune-based therapies, alongside the challenges of translating these advances into routine, equitable care. We open with an editorial […]
Journal Archive
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
